tiprankstipranks
Biogen (BIIB)
NASDAQ:BIIB
US Market
BIIB
Biogen
RESEARCH TOOLSreports

Biogen (BIIB) Stock News & Sentiment

5,002 Followers
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio
Premium
Company Announcements
Biogen to Acquire Apellis, Expanding Ophthalmology Portfolio
12d ago
8K
BIIB
Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
Premium
Market News
Morning News Wrap-Up 3/31/26: Today’s Biggest Stock Market Stories!
12d ago
UL
AMD
M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
Premium
Market News
M&A News: Apellis Pharmaceuticals Stock (APLS) Rockets over 130% after $5.6B Biogen Rare Diseases Deal
12d ago
APLS
BIIB
Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
Premium
Ratings
Biogen: Spinraza HD Approval Supports but Does Not Transform Outlook; Leqembi Execution and MS Erosion Keep Rating at Hold
13d ago
BIIB
Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
Premium
Ratings
Biogen: Incremental Pipeline Progress and Spinraza Update Support Hold Rating Amid Ongoing Uncertainties
13d ago
BIIB
Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold
Premium
Ratings
Biogen (Litifilimab/Lupus): Encouraging Early Data but Competitive and Clinical Risks Support a Neutral Hold
13d ago
BIIB
Balanced but Constrained Upside: Hold Rating on Biogen as Modest Litifilimab Data Meet Rising Lupus Competition
Premium
Ratings
Balanced but Constrained Upside: Hold Rating on Biogen as Modest Litifilimab Data Meet Rising Lupus Competition
14d ago
BIIB
More BIIB News >

BIIB News on the Web

Biogen price target raised to $200 from $190 at Morgan Stanley
TipRanks News
Neutral
Morgan Stanley Keeps Their Hold Rating on Biogen (BIIB)
TipRanks News
Neutral
Gilead Expands Oncology Pipeline With $5B Tubulis Deal
Zacks
Bullish
CNBC Cures: A father and a doctor on how raising a child with Angelman syndrome changed him
CNBC
Neutral
Denali Stock Falls as Partner Takeda Ends Collaboration Deal
Zacks
Neutral
Why Biogen (BIIB) Could Beat Earnings Estimates Again
Zacks
Bullish
Biogen price target lowered to $213 from $233 at RBC Capital
TipRanks News
Neutral
Why Biogen Stock Got Mashed on Monday
The Motley Fool
Bearish

News Score - Last 7 Days

Neutral
BIIB
Sector Average
Media Buzz
This Week10 articles
Weekly Average18.5 articles
News Sentiment
This Week50%
Sector Average68%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is BIIB’s Media Buzz Sentiment?
10 articles about BIIB were published this week. In an average week, 18.5 articles are published.
    What is BIIB’s weekly average amount of articles?
    In an average week, 18.5 articles about BIIB are published.
      What is BIIB’s News Sentiment?
      50% of articles about BIIB were positive this week, compared to its sector average of 68%.
        Healthcare Stocks that are Trending in the News
        AORTArtivion
        NBIXNeurocrine
        STAAStaar Surgical
        SLPSimulations Plus
        OWLTOwlet
        Showing the stocks with the most bullish news sentiment over the past week